Evaxion Biotech A/S
Price Action
Technical Summary
CONSOLIDATINGEvaxion Biotech A/S is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 75), indicating performance broadly in line with the market. Earnings growth of 400% provides fundamental context to the price action. Investors should exercise caution due to high volatility (121% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.29 | +2.88% | ABOVE |
| 50 SMA | $3.90 | +13.01% | ABOVE |
| 100 SMA | $4.13 | +6.87% | ABOVE |
| 150 SMA | $4.76 | -7.28% | BELOW |
| 200 SMA | $4.31 | +2.21% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is EVAX in an uptrend right now?
EVAX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is EVAX overbought or oversold?
EVAX's RSI (14) is 56. The stock is in neutral territory, neither overbought nor oversold.
Is EVAX outperforming the market?
EVAX has a Relative Strength (RS) Rating of 75 out of 99. EVAX is performing about average compared to the market.
Where is EVAX in its 52-week range?
EVAX is trading at $4.41, which is 36% of its 52-week high ($12.15) and 28% above its 52-week low ($1.43).
How volatile is EVAX?
EVAX has a Beta of 1.29 and 52-week volatility of 121%. It's more volatile than the S&P 500 - expect bigger swings.